Latest News
Retatrutide Black Market: Lilly Sues Six US Sellers
Eli Lilly has filed six lawsuits against United States companies. It accuses them of selling illegal versions of its experimental obesity drug, which remains in Phase 3 trials. The retatrutide black market runs through peptide websites, medical spas and wellness...
Latest News
IgA Nephropathy Drug Pipeline Reaches Six Approvals in Five Years
IgA nephropathy, the most common primary glomerulonephritis worldwide, has undergone a remarkable transformation in its treatment landscape. Once managed solely with supportive care and immunosuppression of uncertain benefit, the IgA nephropathy drug pipeline now...
Compliant on Paper, Exposed in Practice
A pharmaceutical manufacturer completes a technology transfer. The validation protocols have been approved. Training records are complete, documentation has been reviewed, and every required signature has been collected. The project passes its milestones and moves...
The One Leadership Skill That Turns the Ordinary Into the Extraordinary
As healthcare and life sciences organizations confront workforce shortages, regulatory pressures, rapid technological change, and increasing operational complexity, building a pipeline of extraordinary leaders has never been more important. Many of these organizations...
From Reactive Reviews to Predictive Regulatory Intelligence
Every regulatory professional has experienced the same moment. After months, and sometimes years, of preparing a Chemistry, Manufacturing, and Controls (CMC) submission, the application is finally submitted to a health authority. At that point, the questions begin....
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters — all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
Strait of Hormuz Closure: The Threat to Global Medicine Supplies
When US and Israeli military operations against Iran began on 28 February 2026, the consequences for global energy markets were immediate and predictable. What was less widely anticipated was the scale of the disruption now rippling through the life sciences sector....
Clinical Trials Roundup | 17 April 2026
Revolution Medicines' daraxonrasib nearly doubles overall survival in previously treated metastatic pancreatic cancer in the Phase 3 RASolute 302 trial, Travere Therapeutics' Filspari receives FDA approval as the first-ever treatment for focal segmental...
UK Government’s LSLIP: A New Era for British Life Science
UK Government's Life Sciences Large Investment Portfolio: A New Era for British Life Science The United Kingdom's life sciences sector received a significant policy boost on 14 April 2026 when the government formally announced the Life Sciences Large Investment...
The UK Spine Crisis: Beyond Posture to a Future of Regenerative Care
The UK is currently navigating a silent epidemic that threatens not only our collective physical well-being but also our national productivity and the long-term sustainability of our healthcare infrastructure. Musculoskeletal (MSK) conditions now impact nearly one in...
Daraxonrasib Phase 3 Trial Results Signal a New Era for Pancreatic Cancer
The daraxonrasib pancreatic cancer trial results announced on 13 April 2026 represent what many in the oncology community are calling a landmark moment for one of medicine's most stubborn and lethal diseases. Revolution Medicines, a late-stage clinical oncology...
How Can At-Home Diagnostics and AI-Enabled Detection Drive Better Health?
The UK government’s 10 Year Health Plan sets a bold ambition for the NHS, shifting from analogue to digital, from hospital to community, and from cure to prevention. For the life sciences sector, this aligns closely with long standing priorities around earlier...
The Rising Reach of Black-Market Prescription Drugs in the UK
Despite common perceptions, the black market is no longer confined to underground, organised crime networks or obscure corners of the internet. In reality, this trade in illegal prescription drugs can be found in a local corner shop, hair salon, or even people’s own...
The Human Microbiome: An Interface Between Lifestyle, Metabolism & Health
For much of modern medicine, microorganisms have been largely viewed through a narrow lens, as agents of infection to be identified and then eliminated. This perspective, whilst undeniably important, captures only part of the story. Over the past two decades, advances...
How Behavioral Science and Machine Learning Can Transform Trial Adherence
It’s ironic that the rigid nature of clinical research depends on a largely fragile variable: people. Even the most promising therapy cannot succeed in development if the study evaluating it struggles to keep participants engaged. Recruiting patients is already a...
Weekly News Roundup | 13 April 2026
Life science news 13 April 2026: A record-breaking wave of M&A, an escalating GLP-1 pricing war and major FDA approvals define a landmark week for the global life science industry. Gilead Sciences announced on 7 April its acquisition of Munich-based antibody-drug...
The Gut Microbiome and the Future of Human Health
The gut microbiome has moved from a niche area of research to one of the most important frontiers in modern medicine. Once associated mainly with digestion, it is now understood to be a complex, organ-like system that influences immunity, metabolism and even brain...
Clinical Trials Roundup | 10 April 2026
Amgen’s subcutaneous reformulation of Tepezza meets its Phase 3 primary endpoint in thyroid eye disease, Lipocine’s oral brexanolone suffers a significant Phase 3 setback in postpartum depression, and NervGen Pharma secures FDA alignment on the RESTORE Phase 3...
Strait of Hormuz Closure: The Threat to Global Medicine Supplies
When US and Israeli military operations against Iran began on 28 February 2026, the consequences for global energy markets were immediate and predictable. What was less widely anticipated was the scale of the disruption now rippling through the life sciences sector....
Clinical Trials Roundup | 17 April 2026
Revolution Medicines' daraxonrasib nearly doubles overall survival in previously treated metastatic pancreatic cancer in the Phase 3 RASolute 302 trial, Travere Therapeutics' Filspari receives FDA approval as the first-ever treatment for focal segmental...
UK Government’s LSLIP: A New Era for British Life Science
UK Government's Life Sciences Large Investment Portfolio: A New Era for British Life Science The United Kingdom's life sciences sector received a significant policy boost on 14 April 2026 when the government formally announced the Life Sciences Large Investment...
The UK Spine Crisis: Beyond Posture to a Future of Regenerative Care
The UK is currently navigating a silent epidemic that threatens not only our collective physical well-being but also our national productivity and the long-term sustainability of our healthcare infrastructure. Musculoskeletal (MSK) conditions now impact nearly one in...
Daraxonrasib Phase 3 Trial Results Signal a New Era for Pancreatic Cancer
The daraxonrasib pancreatic cancer trial results announced on 13 April 2026 represent what many in the oncology community are calling a landmark moment for one of medicine's most stubborn and lethal diseases. Revolution Medicines, a late-stage clinical oncology...
How Can At-Home Diagnostics and AI-Enabled Detection Drive Better Health?
The UK government’s 10 Year Health Plan sets a bold ambition for the NHS, shifting from analogue to digital, from hospital to community, and from cure to prevention. For the life sciences sector, this aligns closely with long standing priorities around earlier...
The Rising Reach of Black-Market Prescription Drugs in the UK
Despite common perceptions, the black market is no longer confined to underground, organised crime networks or obscure corners of the internet. In reality, this trade in illegal prescription drugs can be found in a local corner shop, hair salon, or even people’s own...
The Human Microbiome: An Interface Between Lifestyle, Metabolism & Health
For much of modern medicine, microorganisms have been largely viewed through a narrow lens, as agents of infection to be identified and then eliminated. This perspective, whilst undeniably important, captures only part of the story. Over the past two decades, advances...
How Behavioral Science and Machine Learning Can Transform Trial Adherence
It’s ironic that the rigid nature of clinical research depends on a largely fragile variable: people. Even the most promising therapy cannot succeed in development if the study evaluating it struggles to keep participants engaged. Recruiting patients is already a...
Weekly News Roundup | 13 April 2026
Life science news 13 April 2026: A record-breaking wave of M&A, an escalating GLP-1 pricing war and major FDA approvals define a landmark week for the global life science industry. Gilead Sciences announced on 7 April its acquisition of Munich-based antibody-drug...
The Gut Microbiome and the Future of Human Health
The gut microbiome has moved from a niche area of research to one of the most important frontiers in modern medicine. Once associated mainly with digestion, it is now understood to be a complex, organ-like system that influences immunity, metabolism and even brain...
Clinical Trials Roundup | 10 April 2026
Amgen’s subcutaneous reformulation of Tepezza meets its Phase 3 primary endpoint in thyroid eye disease, Lipocine’s oral brexanolone suffers a significant Phase 3 setback in postpartum depression, and NervGen Pharma secures FDA alignment on the RESTORE Phase 3...
Featured Articles
Further News
The FDA PMTA Roundtable: Initial Reflections
Product characterisation remains the critical test of submission strength The US Food and Drug Administration (FDA) convened a roundtable on the Premarket Tobacco Product Application (PMTA) process, bringing together discussions on product characterisation,...
Beyond the Tumour: Can Radiotherapy Boost the Immune System?
Emerging research from a team of oncologists in Prague suggests that radiotherapy — long understood as a tool for destroying cancer cells — may also play a powerful role in activating the body's own immune defences. The implications for how we sequence and combine...
The Hidden ‘Perfect Healing’ Codes Within Your Body Have Been Deciphered
An axolotl loses its leg to a predator. Four weeks later, it has a functional replacement bones, nerves, muscles, and skin are perfectly re-formed. It is a biological masterpiece that has fascinated science for centuries. For decades, the prevailing dogma in...
Closing the Interventional Gap
The National Health Service (NHS) is investing heavily in diagnostics. Through Getting it Right First Time (GIRFT) and the rollout of Community Diagnostic Centres (CDCs), millions of patients are getting scans more quickly than ever[1]. The NHS 10 Year Plan has now...
Weekly News Roundup | 6 April 2026
Life science news 6 April 2026: A landmark obesity pill approval, 100% pharma tariffs and a record $6.3 billion life sciences fund headline a transformative week for the global pharmaceutical industry. The FDA approved Eli Lilly's once-daily obesity pill Foundayo...
Transforming Clinical Outsourcing: From Reactive to Predictive Strategy
The Growing Strain on Clinical Trial Operations Clinical trials have become increasingly diverse, complex, and expensive over the past decade. As the industry moves toward a more globalized model, managing timelines, coordinating across clinical functions, and...
Natural Diamonds in Healthcare
When we say "diamonds," most people think of a luxurious necklace or a super sparkly ring. A research lab would be the last place people imagine them being used. Interestingly, natural diamonds are getting a lot of attention in science and healthcare research. And...
Clinical Trials Roundup | 03 April 2026
Beam Therapeutics' base edited cell therapy for sickle cell disease earns a landmark NEJM publication, Immunovant's batoclimab misses in two Phase 3 thyroid eye disease trials, Seaport Therapeutics unlocks a novel anxiety treatment pathway, and Eli Lilly's oral GLP-1...
Erectile Dysfunction is Preventable – if You Act Early
Did you know that your erections can tell you more about your heart health than you might think? Nocturnal erections—those spontaneous erections that happen during sleep—are directly tied to vascular health. When a man stops having them, even for a short period of...
Rethinking Lifestyle Diseases: From Risk Factors to Root Causes
Are we mistaking associations for true biological origins? Despite significant advances in modern medicine, lifestyle diseases such as cardiovascular disease and diabetes continue to rise globally. These conditions are commonly described as “multifactorial,”...
Rethinking Commercial Strategy for Late Biopharma Entrants
Being first to market in a new therapeutic class is often seen as a winning formula in biopharma. In reality, many of the biggest commercial successes come second, or even later. The difference is not luck. It is timing, differentiation and scale. Understanding late...
Python Blood Molecule Opens Door to New Obesity Treatments
Scientists studying the extraordinary metabolism of Burmese pythons have identified a python blood molecule that dramatically suppresses appetite in obese mice, raising the prospect of a new class of weight loss therapies that could avoid some of the side effects...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.